IMCIVREE 10 mg/ml solution for injection

DRUG2 trials

Sponsors

Rhythm Pharmaceuticals Inc., Universitair Medisch Centrum Utrecht

Conditions

Improper function of certain messenger materials in the body that control body weight and hunger in peopleROHHAD syndrome

Phase 2

SETmelanotide to improve hypothalamic function in the ROHHAD-syndrome; a proof of concept study in a small mono-center cohort: the ROH-SET Study

RecruitingCTIS2024-516753-45-00

Universitair Medisch Centrum UtrechtROHHAD syndrome

Start: 2025-04-25Target: 5Updated: 2025-03-06

Phase 3

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial: Multiple Independent Sub-studies of Setmelanotide in Patients with POMC/PCSK1, LEPR, NCOA1 (SRC1), or SH2B1 Gene Variants in the Melanocortin-4 Receptor Pathway

Active, not recruitingCTIS2023-507634-24-00

Rhythm Pharmaceuticals Inc.Improper function of certain messenger materials in the body that control body weight and hunger in people

Start: 2022-05-20Target: 85Updated: 2025-11-28